Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Tamoxifen Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women. 1
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive Invasive Breast Carcinoma Tamoxifen
Sensitivity (+) ER positive Invasive Breast Carcinoma Tamoxifen